Intervention Protocol

You have free access to this content

Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for advanced and/or metastatic colorectal cancer

  1. Wahyu Wulaningsih1,*,
  2. Ardyan Wardhana2,
  3. Naomi Yoshuantari3,
  4. Ajeng A Sekarini3,
  5. Mieke Van Hemelrijck4

Editorial Group: Cochrane Colorectal Cancer Group

Published Online: 22 AUG 2013

DOI: 10.1002/14651858.CD008593.pub2


How to Cite

Wulaningsih W, Wardhana A, Yoshuantari N, Sekarini AA, Van Hemelrijck M. Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for advanced and/or metastatic colorectal cancer (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 8. Art. No.: CD008593. DOI: 10.1002/14651858.CD008593.pub2.

Author Information

  1. 1

    Tulip Integrated Cancer Clinic, Faculty of Medicine, Gadjah Mada University, Hematology/Oncology Division, Internal Medicine Department, Yogyakarta, Indonesia

  2. 2

    International SOS, Yogyakarta, Indonesia

  3. 3

    Faculty of Medicine, Gadjah Mada University, Tulip Integrated Cancer Clinic, Hematology/Oncology Division, Internal Medicine Department, Yogyakarta, Indonesia

  4. 4

    King?s College London, School of Medicine,, Division of Cancer Studies, Cancer Epidemiology Group, London, UK

*Wahyu Wulaningsih, Hematology/Oncology Division, Internal Medicine Department, Tulip Integrated Cancer Clinic, Faculty of Medicine, Gadjah Mada University, Jalan Kesehatan No.1 Sekip Yogyakarta, Yogyakarta, Indonesia. wahyu.wulaningsih@yahoo.com.

Publication History

  1. Publication Status: Amended to reflect a change in scope (see 'What's new')
  2. Published Online: 22 AUG 2013

SEARCH

References

Additional references

ACCMAP 1992
  • Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Journal of Clinical Oncology 1992;10(6):896-903.
Cao 2000
  • Cao S, Rustum YM. Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose. Cancer Research 2000;60(14):3717-21.
Center 2009
Chau 2005
  • Chau I, Norman AR, Cunningham D, Iveson T, Hill M, Hickish T, et al. Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer. European Journal of Cancer 2005;41(11):1551-9.
Clarke 2011
  • Clarke SJ, Yip S, Brown C, van Hazel GA, Ransom DT, Goldstein D, et al. Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected]. European Journal of Cancer 2011;47(12):1826-36.
Conti 1996
  • Conti JA, Kemeny NE, Saltz LB, Huang Y, Tong WP, Chou TC, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. Journal of Clinical Oncology 1996;14(3):709-15.
Cunningham 1998
  • Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352(9138):1413-8. [PUBMED: 9807987]
Douillard 2000
  • Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355(9209):1041-7.
Ferlay 2010
Fischel 2001
  • Fischel JL, Rostagno P, Formento P, Dubreuil A, Etienne MC, Milano G. Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines. British Journal of Cancer 2001;84(4):579-85. [PUBMED: 11207057]
Folprecht 2008
  • Folprecht G, Seymour MT, Saltz L, Douillard JY, Hecker H, Stephens RJ, et al. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. Journal of Clinical Oncology 2008;26(9):1443-51.
Giessen 2011
  • Giessen C, von Weikersthal LF, Hinke A, Stintzing S, Kullmann F, Vehling-Kaiser U, et al. A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial. BMC cancer 2011;11:367.
Graeven 2007
  • Graeven U, Arnold D, Reinacher-Schick A, Heuer T, Nusch A, Porschen R, et al. A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma. Onkologie 2007;30(4):169-74.
Higgins 2011
  • Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savović J, Schulz, KF, Weeks L, Sterne JAC, Cochrane Bias Methods Group. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. British Medical Journal 2011;343:d5928.
Hsiang 1985
  • Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. Journal of Biological Chemistry 1985;260(27):14873-8.
Jemal 2011
Kuhry 2008
  • Kuhry E, Schwenk W, Gaupset R, Romild U, Bonjer J. Long-term outcome of laparoscopic surgery for colorectal cancer: a cochrane systematic review of randomised controlled trials. Cancer Treatment Reviews 2008;34(6):498-504.
Maiello 2000
  • Maiello E, Gebbia V, Giuliani F, Paoletti G, Gebbia N, Cigolari S, et al. 5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: a multicenter randomised phase II study of the Southern Italy Oncology Group. Annals of Oncology 2000;11(8):1045-51.
Maiello 2005
  • Maiello E, Gebbia V, Giuliani F, Paoletti G, Gebbia N, Borsellino N, et al. FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Annals of Oncology: Official Journal of the European Society for Medical Oncology / ESMO 2005;16 Suppl 4:iv56-60.
Montagnani 2010
  • Montagnani F, Chiriatti A, Licitra S, Aliberti C, Fiorentini G. Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer. Clinical Colorectal Cancer 2010;9(4):243-7.
Muro 2010
  • Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba H, et al. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). The Lancet Oncology 2010;11(9):853-60.
Oostendorp 2010
  • Oostendorp LJ, Stalmeier PF, Pasker-de Jong PC, Van der Graaf WT, Ottevanger PB. Systematic review of benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer. Anti-cancer Drugs 2010;21(8):749-58.
Parmar 1998
Petrelli 2012
  • Petrelli F, Cabiddu M, Barni S. 5-Fluorouracil or capecitabine in the treatment of advanced colorectal cancer: a pooled-analysis of randomized trials. Medical Oncology 2012;29(2):1020-9.
Pitot 1997
  • Pitot HC, Wender DB, O'Connell MJ, Schroeder G, Goldberg RM, Rubin J, et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. Journal of Clinical Oncology 1997;15(8):2910-9.
Ragnhammar 2001
  • Ragnhammar P, Hafström L, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncologica 2001;40(2-3):282-308.
Rothenberg 1999
Rougier 1997
  • Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. Journal of Clinical Oncology 1997;15(1):251-60.
Rougier 1998
  • Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352(9138):1407-12.
Rougier 2003
  • Rougier P, Mitry E. Epidemiology, treatment and chemoprevention in colorectal cancer. Annals of Oncology: Official journal of the European Society for Medical Oncology / ESMO 2003;14 Suppl 2:ii3-5.
Saltz 2000
  • Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. New England Journal of Medicine 2000;343(13):905-14.
Seymour 2007
  • Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007;370(9582):143-52.
Siegel 2013
Simmonds 2000
  • Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. British Medical Journal 2000;321(7260):531-5.
Therasse 2000
  • Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.. Journal of the National Cancer Institute 2000;92(3):205-16.
Thirion 2004
  • Thirion P, Michiels S, Pignon JP, Buyse M, Braud AC, Carlson RW, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. Journal of Clinical Oncology 2004;22(18):3766-75.
Tierney 2007
Van Cutsem 2004
  • Van Cutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. British Journal of Cancer 2004;90(6):1190-7.